Trials / Suspended
SuspendedNCT05643690
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay in Subjects Suspected of Having Bladder Cancer
- Status
- Suspended
- Phase
- —
- Study type
- Observational
- Enrollment
- 77 (actual)
- Sponsor
- AnchorDx Medical Co. Ltd. US · Industry
- Sex
- All
- Age
- 55 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | UriFind Bladder Cancer Assay | The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients. |
Timeline
- Start date
- 2022-11-18
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2022-12-09
- Last updated
- 2024-06-06
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05643690. Inclusion in this directory is not an endorsement.